(Q39744448)

14 September 2017

title

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma (English)

1 reference

14 September 2017

1 reference

Françoise Kraeber-Bodéré

9

Françoise Kraeber-Bodéré

0 references

Caroline Bodet-Milin

2

Caroline Bodet-Milin

0 references

Catherine Saï-Maurel

5

Catherine Saï-Maurel

0 references

Alain Faivre-Chauvet

6

Alain Faivre-Chauvet

0 references

Pierre-Yves Salaun

Pierre-Yves Salaun

1

0 references

Jacques Barbet

Jacques Barbet

7

0 references

Eric Frampas

3

Eric Frampas

1 reference

14 September 2017

4

Aurore Oudoux

1 reference

14 September 2017

François Paris

8

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

116

1 reference

14 September 2017

issue

4 Suppl

1 reference

14 September 2017

page(s)

1053-1058

1 reference

Association of medullary carcinoma of the thyroid with carcinoembryonic antigen

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Pretargeting with the affinity enhancement system for radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24792

7 January 2021

Identifiers

DOI

10.1002/CNCR.24792

1 reference

14 September 2017

1 reference